Top-News
Pharmazeutika USA

Karyopharm Therapeutics News

Aktie
WKN:  A1W77U ISIN:  US48576U1060 US-Symbol:  KPTI
1,093 €
+0,0435 €
+4,14%
17.05.24 13:01:04
Handeln Depot/Watchlist
Aktienanzahl *
114,53 Mio.
Marktkapitalisierung *
121,18 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 28.11.2023

Karyopharm Therapeutics News

02.11.23 - PR Newswire
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire
30.10.23 - PR Newswire
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients ...
02.10.23 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
26.09.23 - PR Newswire
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings PR ...
05.09.23 - PR Newswire
Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm to Participate at Upcoming Investor Conferences PR Newswire
01.09.23 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.09.23 - PR Newswire
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors PR Newswire
02.08.23 - PR Newswire
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire
01.08.23 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
26.07.23 - PR Newswire
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023 PR Newswire
25.07.23 - PR Newswire
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer ...
19.07.23 - PR Newswire
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ...
18.07.23 - PR Newswire
Thinking about buying stock in Ballard Power Systems, Apellis Pharmaceuticals, Mind Medicine, Nio Inc, or Karyopharm Therapeutics?
Thinking about buying stock in Ballard Power Systems, Apellis Pharmaceuticals, Mind Medicine, Nio Inc, or Karyopharm Therapeutics? PR Newswire
17.07.23 - PR Newswire
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis PR Newswire
05.07.23 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
28.06.23 - PR Newswire
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis PR Newswire
01.06.23 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.06.23 - PR Newswire
Karyopharm to Participate at the Jefferies Healthcare Conference
Karyopharm to Participate at the Jefferies Healthcare Conference PR Newswire
23.05.23 - PR Newswire
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings PR Newswire
04.05.23 - PR Newswire
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »